The estimated Net Worth of Mo Qatanani is at least $1.81 Millón dollars as of 17 June 2024. Mo Qatanani owns over 2,315 units of Scholar Rock Corp stock worth over $1,257,478 and over the last few years Mo sold SRRK stock worth over $552,929.
Mo has made over 5 trades of the Scholar Rock Corp stock since 2023, according to the Form 4 filled with the SEC. Most recently Mo sold 2,315 units of SRRK stock worth $20,812 on 17 June 2024.
The largest trade Mo's ever made was selling 24,662 units of Scholar Rock Corp stock on 14 December 2023 worth over $448,355. On average, Mo trades about 5,573 units every 46 days since 2023. As of 17 June 2024 Mo still owns at least 144,704 units of Scholar Rock Corp stock.
You can see the complete history of Mo Qatanani stock trades at the bottom of the page.
Over the last 6 years, insiders at Scholar Rock Corp have traded over $8,613,447 worth of Scholar Rock Corp stock and bought 8,895,194 units worth $64,726,758 . The most active insiders traders include Timothy A Springer, Srinivas Akkaraju y Amir Nashat. On average, Scholar Rock Corp executives and independent directors trade stock every 55 days with the average trade being worth of $1,953,616. The most recent stock trade was executed by Caryn Parlavecchio on 16 August 2024, trading 1,451 units of SRRK stock currently worth $13,538.
scholar rock® is a biotechnology company focused on discovering and developing a new class of biologic therapies called "niche modulators" that selectively target the activation of growth factors in the disease microenvironment. our initial proprietary and partnered drug discovery programs target specific growth factors, including members of the tgf-beta superfamily, which play a fundamental role in regulating cell growth and differentiation and are present in the microenvironments of significant diseases such as fibrosis, diseases of the musculoskeletal systems, and autoimmune diseases. the company’s therapeutic approach is enabled by discoveries made by scholar rock’s scientific founders—professors timothy springer, phd, and leonard zon, md, both of children's hospital boston and harvard medical school—related to the molecular mechanisms of growth factor activation. scholar rock is backed by leading life sciences investors, including polaris partners, arch venture partners, timothy s
Scholar Rock Corp executives and other stock owners filed with the SEC include: